Pranata R, Permana H, Huang I, Lim MA, Soetedjo NNM, Supriyadi R, et al. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14:983–90.

Article  PubMed  PubMed Central  Google Scholar 

Caldeira D, Alves M, Gouveia E Melo R, Silvério António P, Cunha N, Nunes-Ferreira A, et al. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2020;31:100627.

PubMed  PubMed Central  Google Scholar 

Alamer AA, Almulhim AS, Alrashed AA, Abraham I. Mortality, severity, and hospital admission among COVID-19 patients with ACEI/ARB Use: A meta-analysis stratifying countries based on response to the first wave of the pandemic. Healthcare. 2021;9:127.

Article  PubMed  PubMed Central  Google Scholar 

Patoulias D, Katsimardou A, Stavropoulos K, Imprialos K, Kalogirou MS, Doumas M. Renin-angiotensin system inhibitors and COVID-19: a systematic review and meta-analysis. evidence for significant geographical disparities. Curr Hypertens Rep. 2020;22:90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshihara F, Ohtsu H, Nakai M, Tsuzuki S, Hayakawa K, Terada M, et al. Renin-angiotensin system blocker and the COVID-19 aggravation in patients with hypertension, diabetes, renal failure, Cerebro-cardiovascular disease, or pulmonary disease: Report by the COVID-19 Registry Japan. J Cardiol. 2022;80:292–97.

Article  PubMed  PubMed Central  Google Scholar 

Abraham HM, White CM, White WB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf. 2015;38:33–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens. 1998;11:445–53.

Article  CAS  PubMed  Google Scholar 

White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens. 2004;17:347–53.

Article  CAS  PubMed  Google Scholar 

Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertension. 2001;3:283–91.

Article  CAS  Google Scholar 

Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res. 2012;35:552–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santosa A, Franzén S, Nåtman J, Wettermark B, Parmryd I, Nyberg F. Protective effects of statins on COVID-19 risk, severity and fatal outcome: a nationwide Swedish cohort study. Sci Rep. 2022;12:12047.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saad M, Kennedy KF, Louis DW, Imran H, Sherrod CF 4th, Aspry K, et al. Preadmission statin treatment and outcome in patients hospitalized with COVID-19. Am J Cardiol. 2022;177:28–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bouillon K, Baricault B, Semenzato L, Botton J, Bertrand M, Drouin J, et al. Association of statins for primary prevention of cardiovascular diseases with hospitalization for COVID-19: A nationwide matched population-based cohort study. J Am Heart Assoc. 2022;11:e023357.

Article  PubMed  PubMed Central  Google Scholar 

Kollias A, Kyriakoulis KG, Kyriakoulis IG, Nitsotolis T, Poulakou G, Stergiou GS, et al. Statin use and mortality in COVID-19 patients: Updated systematic review and meta-analysis. Atherosclerosis. 2021;330:114–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diaz-Arocutipa C, Melgar-Talavera B, Alvarado-Yarasca Á, Saravia-Bartra MM, Cazorla P, Belzusarri I, et al. Statins reduce mortality in patients with COVID-19: an updated meta-analysis of 147 824 patients. Int J Infect Dis. 2021;110:374–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020;180:1345–55.

Article  CAS  PubMed  Google Scholar 

Hariyanto TI, Kurniawan A. Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression. Nutr Metab Cardiovasc Dis. 2021;31:1662–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cariou B, Goronflot T, Rimbert A, Boullu S, Le May C, Moulin P, et al. Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study. Diabetes Metab. 2021;47:101202.

Article  CAS  PubMed  Google Scholar 

Garin N, Koyanagi A, Chatterji S, Tyrovolas S, Olaya B, Leonardi M, et al. Global multimorbidity patterns: a cross-sectional, population-based, multi-country study. J Gerontol A Biol Sci Med Sci. 2016;71:205–14.

Article  PubMed  Google Scholar 

Jani BD, Hanlon P, Nicholl BI, McQueenie R, Gallacher KI, Lee D, et al. Relationship between multimorbidity, demographic factors and mortality: findings from the UK Biobank cohort. BMC Med. 2019;17:74.

Article  PubMed  PubMed Central  Google Scholar 

Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 2015;13:74.

Article  PubMed  PubMed Central  Google Scholar 

Iloanusi S, Mgbere O, Essien EJ. Polypharmacy among COVID-19 patients: A systematic review. J Am Pharm Assoc (2003). 2021;61:e14–e25.

Article  CAS  PubMed  Google Scholar 

Sirois C, Boiteau V, Chiu Y, Gilca R, Simard M. Exploring the associations between polypharmacy and COVID-19-related hospitalisations and deaths: a population-based cohort study among older adults in Quebec, Canada. BMJ Open. 2022;12:e060295.

Article  PubMed  Google Scholar 

McQueenie R, Foster HME, Jani BD, Katikireddi SV, Sattar N, Pell JP, et al. Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort. PLoS One. 2020;15:e0238091.

Article  CAS  PubMed  PubMed Central  Google Scholar 

R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. (2021) URL https://www.R-project.org/.

Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67:1–48. https://doi.org/10.18637/jss.v067.i01

Article  Google Scholar 

Mikami T, Miyashita H, Yamada T, Harrington M, Steinberg D, Dunn A, et al. Risk factors for mortality in patients with COVID-19 in New York City. J Gen Intern Med. 2021;36:17–26.

Article  PubMed  Google Scholar 

Pandita A, Gillani FS, Shi Y, Hardesty A, McCarthy M, Aridi J, et al. Predictors of severity and mortality among patients hospitalized with COVID-19 in Rhode Island. PLoS One. 2021;16:e0252411.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duarte M, Pelorosso F, Nicolosi LN, Salgado MV, Vetulli H, Aquieri A, et al. Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial. EClinicalMedicine. 2021;37:100962.

Article  PubMed  PubMed Central  Google Scholar 

Writing Committee for the REMAP-CAP Investigators, Lawler PR, Derde LPG, van de Veerdonk FL, McVerry BJ, Huang DT, et al. Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19: A randomized clinical trial. JAMA 2023;329:1183–96.

Article  PubMed Central  Google Scholar 

Ikari Y, Matsue Y, Torii S, Hasegawa M, Aihara K, Kuroda S, et al. Association between statin use prior to admission and lower Coronavirus disease 2019 (COVID-19) severity in patients with cardiovascular disease or risk factors. Circ J. 2021;85:939–43.

Article  CAS  PubMed  Google Scholar 

Higuchi T, Nishida T, Iwahashi H, Morimura O, Otani Y, Okauchi Y, et al. Early clinical factors predicting the development of critical disease in Japanese patients with COVID-19: A single-center, retrospective, observational study. J Med Virol. 2021;93:2141–48.

Article  CAS  PubMed  Google Scholar 

INSPIRATION-S Investigators. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial. BMJ. 2022;376:e068407.

Google Scholar 

Matli K, Al Kotob A, Jamaleddine W, Al Osta S, Salameh P, Tabbikha R, et al. Managing endothelial dysfunction in COVID-19 with statins, beta blockers, nicorandil, and oral supplements: A pilot, double-blind, placebo-controlled, randomized clinical trial. Clin Transl Sci. 2022;15:2323–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis. 2008;198:22–8.

Article  CAS  PubMed